- Home
- NBTX vs PCN Comparison
NBTX vs PCN Comparison
Compare NBTX & PCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- PCN
- Stock Information
- Founded
- NBTX 2003
- PCN 2001
- Country
- NBTX France
- PCN United States
- Employees
- NBTX N/A
- PCN N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- PCN Investment Managers
- Sector
- NBTX Health Care
- PCN Finance
- Exchange
- NBTX Nasdaq
- PCN Nasdaq
- Market Cap
- NBTX 868.8M
- PCN 901.8M
- IPO Year
- NBTX 2020
- PCN N/A
- Fundamental
- Price
- NBTX $21.04
- PCN $13.44
- Analyst Decision
- NBTX Strong Buy
- PCN
- Analyst Count
- NBTX 1
- PCN 0
- Target Price
- NBTX $8.00
- PCN N/A
- AVG Volume (30 Days)
- NBTX 112.7K
- PCN 218.7K
- Earning Date
- NBTX 09-30-2025
- PCN 01-01-0001
- Dividend Yield
- NBTX N/A
- PCN 9.73%
- EPS Growth
- NBTX N/A
- PCN N/A
- EPS
- NBTX N/A
- PCN N/A
- Revenue
- NBTX $11,930,711.00
- PCN N/A
- Revenue This Year
- NBTX N/A
- PCN N/A
- Revenue Next Year
- NBTX $74.67
- PCN N/A
- P/E Ratio
- NBTX N/A
- PCN N/A
- Revenue Growth
- NBTX N/A
- PCN N/A
- 52 Week Low
- NBTX $2.76
- PCN $10.70
- 52 Week High
- NBTX $22.51
- PCN $14.48
- Technical
- Relative Strength Index (RSI)
- NBTX 71.69
- PCN 72.55
- Support Level
- NBTX $19.11
- PCN $13.30
- Resistance Level
- NBTX $22.64
- PCN $13.46
- Average True Range (ATR)
- NBTX 1.64
- PCN 0.07
- MACD
- NBTX 0.63
- PCN -0.01
- Stochastic Oscillator
- NBTX 83.03
- PCN 85.79
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About PCN Pimco Corporate & Income Strategy Fund
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.